Navigation Links
TrialNetworks Sees Strong Growth in Demand for its Clinical Trial Optimization System as Pharma Seeks Technology to Improve Operations Quality and Efficiency
Date:11/7/2013

Needham, MA (PRWEB) November 07, 2013

TrialNetworks provides clinical trial sponsors and CROs with the industry’s only Clinical Trial Optimization System used to improve the quality and efficiency of study operations from startup through closeout. The company has seen rapid growth in demand for its technology as pharma companies have become increasingly aware of the innovative technology and the proven benefits it provides for global feasibility, site activation, patient recruitment, patient retention, site engagement, trial conduct and more.

During Q3 2013, the TrialNetworks platform was implemented for use on more trials than all of 2012. The company attributes this significant growth to three key factors:

  • Proven Value: Due to the real-world improvements experienced by customers using TrialNetworks for the first time, nearly every sponsor that implemented the TrialNetworks platform for a single trial subsequently added additional trials.
  • Market Awareness: Over time, more companies are gaining exposure to the innovative system, often through published articles, case studies and conferences where its benefits are being presented by existing customers.
  • New Apps and Exclusive Features: TrialNetworks continually works with clients to understand requirements and develop new apps and features to fulfill unmet needs, such as Survey™ for feasibility assessments, Directory™ for trial contact management and Checklist™ for efficient site startup and closeout.
Additional milestones achieved by TrialNetworks in Q3 2013 included:
  • 30% growth in employees to support increased demand
  • 25,000th person logged onto the Clinical Trial Optimization System
  • Coverage of the TrialNetworks platform in Clinical Informatics News (featuring customer experiences from Merck & Co.) and Mass High Tech
  • 10,000th "commit" to source code repository for software updates and feature additions
TrialNetworks Co-Founder and CEO Eric Silberstein said, "Sponsors want to use the TrialNetworks platform because in a world of greater trial complexity and strategic outsourcing models, innovative technology is the best way to improve the transparency, quality and efficiency of clinical operations. As more people hear about the benefits of TrialNetworks and as we expand our apps we have seen demand from existing customers and prospective sponsors increase across the board – from biotechs without marketed products to top global pharmaceutical companies."

About TrialNetworks

TrialNetworks provides sponsors and CROs the industry's only Clinical Trial Optimization System. Using this modern and intuitive technology, customers such as Merck & Co. and Infinity Pharmaceuticals are able to transform the quality and efficiency of clinical operations at each stage of a trial from feasibility through closeout. TrialNetworks apps, including Checklist™, Training™, Document Library™, Visit Guide™, Action Items™ and Directory™, are available in a unified and secure cloud-based interface. Customers ranging from biotechs to Top-10 pharma companies have implemented the TrialNetworks platform for use in Phase I-IV trials by more than 25,000 site staff in 60 countries. To learn why sponsors and CROs rely on TrialNetworks to optimize clinical trial operations, request a guided online demo at http://www.trialnetworks.com.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11280148.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. TrialNetworks Feasibility Survey™ App Gets ARIAD Pharmaceuticals Unprecedented 75% Response from Potential Clinical Trial Investigator Sites
2. TrialNetworks Customer to Present Results of Using Site Engagement Technology to Improve Study Operations and Patient Enrollment at Clinical Trial Optimization Conference
3. Terascala Closes Additional Funding Based on Strong OEM Sales and Release of ISB
4. Shire plc: Strong Third Quarter and Increased Non GAAP Earnings Expectations
5. New SPIE Open Access Publishing Program Wins Strong Participation
6. Industries Show Strong Support for 2B Monthly-The Global Biocontrol & Biostimulants Newsletter
7. California Physical Therapy Association Strongly Supports the "Promoting Integrity in Medicare Act" to Fight Self-Referral of Physical Therapist Services
8. Global Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline: MarketResearchReports.Biz
9. Bed Bugs Bum Rides on Taxis, Use of Non-Pesticide Bed Bug Spray Recommended by My Cleaning Products to Kill the Pests Without Strong Chemicals' Help
10. UNL teams discovery yields supertough, strong nanofibers
11. NW Bio 2012 Annual Report Shows Strong Progress And Enhancement Of Leadership Position
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... ... the CHI SCOPE Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). ... to examine vital clinical research issues such as trial performance metrics, patient enrollment ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, the leading ... by its Science Editor, Dr. Elisabeth Bik, in the December 2016 issue of ... joined uBiome in October 2016 from her previous position at Stanford University School ...
(Date:1/18/2017)... Shareholder rights law firm Johnson & Weaver, ... members of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD ... proposed sale of the Company to Eli Lilly and ... molecules for the acute treatment of migraines. ... a definitive merger agreement with Eli Lilly. Under the ...
(Date:1/18/2017)... Jan. 18, 2017  Caris Life Sciences, a ... Foundation, the largest private funder of pancreatic cancer ... evaluating the impact of immunotherapy in the treatment ... enrollment services to identify potential trial candidates based ... treating physicians and study investigators. The Lustgarten Foundation ...
Breaking Biology Technology:
(Date:12/16/2016)...   IdentyTechSolutions America LLC , a leading ... and a cutting-edge manufacturer of software and hardware ... seamless, integrated solutions that comprise IDT biometric readers ... provide IdentyTech,s customers with combined physical identification and ... and theft. "We are proud to ...
(Date:12/15/2016)... 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... announced today that on December 13, 2016, it received ... Nasdaq Stock Market LLC which acknowledged that, as of ... common stock had been at $1.00 or greater for ... with Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
Breaking Biology News(10 mins):